Anika Therapeutics (ANIK) Total Liabilities (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Total Liabilities of $183.5 million for Q2 2026, down 2.24% year-over-year from $187.7 million in Q2 2025, and up 2.28% quarter-over-quarter from $179.4 million in Q1 2026.
Anika Therapeutics (ANIK) Total Liabilities (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Total Liabilities for 17 consecutive years, with $183.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Liabilities fell 2.24% year-over-year to $183.5 million; the TTM figure through Jun 2026 stood at $183.5 million (down 2.24% YoY), while the FY2025 annual figure was $190.3 million, down 6.15% from the prior year.
- Total Liabilities improved to $183.5 million in Q2 2026 per ANIK's latest filing, from $179.4 million in the prior quarter.
- Across five years, Total Liabilities topped out at $354.1 million in Q2 2022 and bottomed at $179.4 million in Q1 2026.
- Historically, Total Liabilities has averaged $263.4 million across 5 years, with a median of $263.2 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities gained 0.46% — and 2024, when it retreated 29.48%.
- Anika Therapeutics' Total Liabilities stood at $349.1 million in 2022, then slipped by 22.48% to $270.6 million in 2023, then decreased by 25.09% to $202.7 million in 2024, then slipped by 6.15% to $190.3 million in 2025, then declined by 3.57% to $183.5 million in 2026.
- Business Quant data shows ANIK's Total Liabilities at $183.5 million in Q2 2026, $179.4 million in Q1 2026, and $190.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.12 Bn |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn | 183.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 183.47 Mn |
| Mar 31, 2026 | 179.39 Mn |
| Dec 31, 2025 | 190.27 Mn |
| Sep 30, 2025 | 189.44 Mn |
| Jun 30, 2025 | 187.68 Mn |
| Mar 31, 2025 | 190.61 Mn |
| Dec 31, 2024 | 202.74 Mn |
| Sep 30, 2024 | 231.41 Mn |
| Jun 30, 2024 | 262.66 Mn |
| Mar 31, 2024 | 263.74 Mn |
| Dec 31, 2023 | 270.63 Mn |
| Sep 30, 2023 | 328.16 Mn |
| Jun 30, 2023 | 328.88 Mn |
| Mar 31, 2023 | 339.07 Mn |
| Dec 31, 2022 | 349.13 Mn |
| Sep 30, 2022 | 347.75 Mn |
| Jun 30, 2022 | 354.12 Mn |
| Mar 31, 2022 | 342.24 Mn |
| Dec 31, 2021 | 347.54 Mn |
| Sep 30, 2021 | 352.93 Mn |